Exploitation of silicon medicinal chemistry in drug discovery

Bibliography

• DIMASI JA, HANSEN RW, HG, LASAGNA L: Cost of innovation in the pharmaceutical industry. Journal Health Econ. (1991) 10:107–142
   PubMed Web of Science ®Google Scholar
• DIMASI JA, HANSEN RW, OWSKI HG: The price of innovation; new estimates of drug development costs. Journal Health Econ. (2003) 22:151–185
   PubMed Web of Science ®Google Scholar
• DREWS J: Strategic trends in the drug industry. Drug Discovery Today (2003) 8:411–420
   PubMed Web of Science ®Google Scholar
• HOPKINS AL, GROOM CR: The druggable genome. Nature Rev Drug. Disc. (2002) 1(9):727–730
   PubMed Web of Science ®Google Scholar
• BOOTH B, ZEMMEL R: Quest for the. Nature Rev Drug. Disc. (2003) 2:838–841
   PubMed Web of Science ®Google Scholar
• SHOWELL GA, MILLS JS: Chemistry challenges in lead optimization: silicon isosteres in drug discovery. Drug Discov. Today (2003) 8(12):551–556
   PubMed Web of Science ®Google Scholar
• MITCHELL T, SHOWELL GA: Design strategies for building drug-like libraries. Carr. Opin. Drug Discov. Dev. (2001) 4:314–318
   PubMedGoogle Scholar
• BAINS W, TACKE R: Silicon chemistry as a novel source of chemical diversity in drug design. Carr. Opin. Drug Discov. Dev. (2003) 6(4):526–543
   PubMed Web of Science ®Google Scholar
• TACKE R, WANNAGAT U: Synthesis and properties of bioactive organo-silicon compounds. Top. Carr. Chem. (1979) 84:1–75
   PubMedGoogle Scholar
• REICHSTAT MM et al.: Theoretical investigation of intermolecular hydrogen-bonded complexes in systems: substituted carbinols (silanols) - ketones or ethers. Smart. (1991) 244:283–290
   Google Scholar
• HOLTJE HD, BUSCH T: Theoretische untersuchungen an sila-analogen anticholinergika. Dtsch. Apoth. Ztg. (1986) 38:2007–2011
   Google Scholar
• WOO DV, CHRISTIAN JE et al: Pharmacological activity comparisons of barbiturates and their silicon analogues. Can. Pharm. Sci. (1979) 14:12–14
   Web of Science ®Google Scholar
• TACKE R, PIKIES J, LINOH H, ROHR-AEHLE R, GOENNE S: Sila-procyclidin: eine neue synthese sowie untersuchungen zur peripheren und zentralen anticholinergen wirkung. Liebigs Ann. Chem. (1987) (1):51–57
   Google Scholar
• CLARK DE: In silicoprediction of blood-brain barrier permeation. Drug Discov. Today (2003) 8(20):927–933
   PubMed Web of Science ®Google Scholar
• WA MUTAHI M, NITTOLI T, GUO L, SIEBURTH SM: Silicon-based metalloprotease inhibitors: synthesis and evaluation of silanol and silanediol peptide analogues as inhibitors of angiotensin-converting enzyme../. Amer. Chem. Soc. (2002) 124(25):7363–7375
   Google Scholar
• CHEN CA, SIEBURTH SM, GLEKAS A et al.: Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. Chem. Biol. (2001) 8(12):1161–1166
   PubMed Web of Science ®Google Scholar
• COOPER JB: Aspartyl proteases in disease: a structural perspective. Curr. Drug Targets (2002) 3(2):155–173
   PubMed Web of Science ®Google Scholar
• PATCHETT AA, NARGUND RP: Privileged structures - an update. Ann. Rep.. Chem. (2000) 35:289–29831.
   Web of Science ®Google Scholar
• PATCHETT AA: 2002 Alfred Burger award address in medicinal chemistry. Natural products and design: interrelated in drug discovery.' Med. Chem.32.(2002) 45(26):5609–5616
   Google Scholar
• LEUNG D, ABBENANTE G, DP: Protease inhibitors: current status and future prospects.' Med. Chem. (2000) 43(3):305–341
   Google Scholar
• KURUP A, MEKAPATI SB, GARG R, C: HIV-1 protease inhibitors: a33.comparative QSAR analysis. Curt: Med.. (2003) 10(17):1679–1688
   Google Scholar
• SIEBURTH SM, NITTOLI T, AM, GUO L: Silanediols: a new34.class of potent protease inhibitors. Angew.. hat. Ed. (1998) 37:812–814
   Google Scholar
• SOUTHAN C: A genome perspective on human proteases. FEBS Lett. (2001) 498:214–218
   PubMed Web of Science ®Google Scholar
• SOUTHAN C: A genome perspective on human proteases as drug targets. Drug Discov. Today (2001) 6(13):681–688
   PubMed Web of Science ®Google Scholar
• DAVEY J: G-protein-coupled receptors: new approaches to maximise the impact of GPCRs in drug discovery. Expert Opin. Ther. Targets (2004) 8(2):165–170
   PubMed Web of Science ®Google Scholar
• CHALMERS DT, BEHAN DP: The use of constitutively active GPCRs in drug discovery and functional genomics. Nature Rev Drug. Disc. (2002) 1(8):599–608
   PubMed Web of Science ®Google Scholar
• BIRCH PJ, DEKKER LV, JAMES IF, SOUTHAN A, CRONK D: Strategies to identify ion channel modulators: current and novel approaches to target neuropathic pain. Drug Discov. Today (2004) 9(9):410–418
   PubMed Web of Science ®Google Scholar
• STASCH J-P, RUSS H, SCLACHT U et al.: 4,4-Diphenylpiperidine derivatives and their sila analogues. Arzneim.-Forsch./ Drug Res. (1988) 38(II)(8):1075–1078
   Google Scholar
• WETZEL JM, MIAO SW, FORRAY C, BORDEN LA, BRANCHEK TA, GLUCHOWSKI C: Discovery of adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.. Chem. (1995) 38(10):1579–1581
   Google Scholar
• HEINRICH T, BURSCHKA C, WARNECK J, TACKE R: Synthesis and pharmacological properties of silicon-containing 1,4-dihydropyridine derivatives: calcium channel antagonists and al adrenoceptor antagonists of the type. Organometallics (2004) 23(3):361–366
   Web of Science ®Google Scholar
• GARSON LR, KIRCHNER LK: Organosilicon entities as prophylactic and therapeutic agents. I Pharm. ScL (1971) 60:1113–1127
   PubMed Web of Science ®Google Scholar
• FARKAS S, KOCSIS P, BIELIK N, GÈMESI L, TRAFIKANT G: Analysis of the mechanism of action, relationship between pharmacodynamics and pharmacokinetics of silperisone, a new centrally acting muscle relaxant. Fun dam. Clin. Pharmacol (1999) 13(1):P5144
   Google Scholar
• BRUFANI M, FILOCAMO L, LAPPA S, MAGGI A: New acetylcholinesterase inhibitors. Drug Future (1997) 22(4):397–410
   Google Scholar
• CUTLER NR, SEIFERT RD, SCHLEMAN MM et al.: Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics. Clin. Pharmacol Ther. (1995) 58(1):54–61
   PubMed Web of Science ®Google Scholar
• PALAZZOLO RJ, McHARD JA, EJ, FANCHER OE, CALANDRA JC: Investigation of the toxicologic properties of a phenylmethylcyclosiloxane. Toxicol Appl. Pharmacol (1972) 21:15–28
   Google Scholar
• ALFTHAN 0, ANDERSSON L, ESPOSTI PL et al: Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study. Scand. I Uron. Nephrol (1983) 17(1):37–43
   PubMed Web of Science ®Google Scholar
• COLLSTE L, BERLIN T, VON GARRELTS B, GRANBERG I, LEWANDER R: Clinical trial of a new antigonadotropic substance, 2,6-cis-diphenylhexamethylcyclotetrasiloxane, in cancer of the prostate. A pilot study. Eur. Urol. (1981) 7(2):85–88
   PubMed Web of Science ®Google Scholar
• ANDERSON CY, FREYE K, KA et al: A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumours inC3H mice. Photochem. Photobiol (2004) 67(3)332–336
   Google Scholar
• KURIE J, HONG WK, KHURI F et al: A dose-escalation, pharmacokinetic and safety study of oral TAC-101 in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol (2000) 19:749
   Google Scholar
• RIZVI NA, MARSHALL JL, NESS E et al: Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-a selective retinoid, in patients with advanced cancer. J. Clin. Oncol (2002) 20(16):3522–3532
   PubMed Web of Science ®Google Scholar
• SCHILSKY R, HAUSHEER F, D, BERGHORN E, KINDLER H, RATAIN M: Phase I trial of karenitecin (KT) administered intravenously daily for five consecutive days in patients with advance solid tumours using accelerated dose titration. Proc. Soc. Clin. Oncol. (2000) 19:758
   Google Scholar
• BURRILL GS: Drug Discovery World, 2003/2004, 9–11
   Google Scholar